Open AccessImpact of 2018 ASCO/CAP guidelines on HER‐2 reporting categories of IHC and reflex FISH in breast cancer
Author(s) -
Pasricha Sunil,
Me Vidya,
Gupta Gurudutt,
Kamboj Meenakshi,
Sharma Anila,
Durga Garima,
Tripathi Rupal,
Batra Ullas,
Jajodia Ankush,
Koyyala Venkata Pradeep Babu,
Agrawal Chaturbhuj,
Doval Dinesh C.,
Mehta Anurag
Publication year - 2020
Publication title -
the breast journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.533
H-Index - 72
eISSN - 1524-4741
pISSN - 1075-122X
DOI - 10.1111/tbj.14031
Subject(s) - medicine , breast cancer , oncology , human epidermal growth factor receptor 2 , fish <actinopterygii> , cancer , biomarker , immunohistochemistry , predictive value , gynecology , fishery , biology , biochemistry , chemistry
Human epidermal growth factor receptor 2 (HER‐2) is an established prognostic and predictive biomarker for breast cancer. To ensure accuracy and uniformity for HER‐2 testing, ASCO/CAP published guidelines in 2007 which were updated in 2013 and recently in 2018. In this first study from Indian Oncology center, we evaluated the impact of 2018 ASCO/CAP guidelines. We found a substantial decrease in equivocal IHC cases ( P ‐value < .00001). On reclassification, a total of 5.6% cases from equivocal and positive categories (2013 guidelines) shifted to the negative FISH result category ( P ‐value < .0001), with adoption of 2018 guidelines and eliminated the double equivocal cases.